

Ministry of Health and Long-Term Care

Ontario Public Drug Programs

Drug Submission Status

| | |
|----------------------|--|
| Generic Name: | dexamethasone |
| Brand Name: | Ozurdex |
| Strength: | 0.7mg intravitreal implant |
| Manufacturer: | Allergan Inc. |
| Indication: | For the treatment of macular edema following central retinal vein occlusion (CRVO) |
| Rapid Review: | Not requested |

| Submission Type: | Date Submission Received: | Date Submission Deemed Complete: | Review Status: | Funding Decision: |
|--------------------------------------|----------------------------------|---|-----------------------|---|
| First Review (Initial Submission) | 08/02/2012 | 24/02/2012 | EO decision rendered | Funding not considered through Ontario Public Drug Programs |

Rapid Review:

Details of the Rapid Review process can be found at:

www.health.gov.on.ca/english/providers/program/drugs/drug_submissions/rapid_review_process.html

Review Status:

- Screening – Ministry is screening the manufacturer's submission to ensure all regulatory and policy requirements have been met in order to proceed with the drug review.
- Submission incomplete – Manufacturer did not meet the necessary requirements to allow review to proceed.
- Submission complete & under review – Manufacturer met all requirements to proceed with the drug review, and evaluation of the drug submission is underway.
- Committee to Evaluate Drugs (CED) review completed, manufacturer requesting reconsideration – A recommendation was made by the CED, however the manufacturer has submitted or will be submitting additional information.
- Committee to Evaluate Drugs (CED) review completed – A recommendation was made by the CED.
- Executive Officer (EO) decision rendered.

Funding Decision:

The Committee to Evaluate Drugs (CED) recommendation and the Executive Officer (EO) decision, if available, can be found at: www.health.gov.on.ca/english/providers/program/drugs/ced_rec_table.html

Updated: August 16, 2012